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Available online 22 April 2016In the present study,we combined stem cell technologywith a non-absorbable biomaterial for the reconstruction
of the ruptured ACL. Towards this purpose,multipotential stromal cells derived either from subcutaneous human
adipose tissue (hAT-MSCs) or from induced pluripotent stem cells (iPSCs) generated from human foreskin ﬁbro-
blasts (hiPSC-MSCs) were cultured on the biomaterial for 21 days in vitro to generate a 3D bioartiﬁcal ACL graft.
Stem cell differentiation towards bone and ligament at the ends and central part of the biomaterial was selective-
ly induced using either BMP-2/FGF-2 or TGF-β/FGF-2 combinations, respectively. The bioartiﬁcial ACL graft was
subsequently implanted in a swine ACL rupture model in place of the surgically removed normal ACL. Four
monthspost-implantation, the tissue engineeredACL graft generated anACL-like tissue exhibitingmorphological
and biochemical characteristics resembling those of normal ACL.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Bioartiﬁcial ACL graft1. Introduction
Regenerative medicine (RM) is an interdisciplinary ﬁeld of research
and clinical applications focus on the repair, replacement, or regenera-
tion of cells, tissues and organs to restore impaired function. RM
employs technological breakthroughs such as those used in tissue engi-
neering (TE) (i.e. biodegradable, biomimetic biopolymers, nanotechnol-
ogy, biosensors etc) in combination with the powerful differentiation
capacity of stem cells. Indeed, adipose tissue (AT) is a rich source ofmul-
tipotential stromal cells (MSCs) that can be successfully differentiated
towards mesoderm-related lineages such as osteoblasts, adipocytes,
chondroblasts and ﬁbroblasts representing a good overall option for.2016.05.006.
Research, Institute of Molecular
Technology-Hellas, University
. This is an open access article underautologous regenerative applications. Adult tissues, however, contain
only committed stem cells that are multi- or even oligopotent. The use
of human embryonic stem cells (hESCs) for medical applications is
prohibited for legal/ethical (commercialization of life) andmedical (im-
mune rejection of heterologous tissue) reasons. Thus, generation of in-
duced pluripotent stem cells (iPSCs) by reprogramming of terminally
differentiated cells (Takahashi and Yamanaka, 2006) offers the possibil-
ity for autologous regeneration of any tissue using pluripotent stem
cells.
Anterior cruciate ligament (ACL) is critical for the stability of the
knee and ACL rupture results in meniscal and cartilage damage leading
to early osteoarthritis. Current repair methods suffer from the low
healing capacity of the ACL, and from the postoperative consequences
of ACL reconstruction approaches, such as osteoarthritis (OA) (Leong
et al., 2013), originate from modiﬁed joint mechanics as a result of
lack of ﬁdelity in the anatomic insertion and alignment of the ligament,
and loss of tissue with neurosensory function (Kiapour and Murray,
2014). The combined potential of RM and TE can be used both in repair
and reconstruction ACL therapies. Both had been proven to be a difﬁcult
task, but generating a bioartiﬁcial ACL poses a particular challenge duethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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has to be induced to differentiate towards a ﬁbrous middle part
representing the ACL ligament and two osseous components, one at
each end of the construct, forming the bone attachment points. To the
best of our knowledge, such an approach, closely simulating the struc-
ture of the human ACL has not been reported in the literature. Thus, in
the present study, we have evaluated the possibility of developing a tis-
sue engineered construct for the regeneration of ACL based on the above
approach establishing the appropriate conditions and comparing the
suitability of hAT-MSCs and hiPSC-MSCs for this purpose.
2. Materials & methods
The derivation and culturing conditions of hAT-MSCs are thoroughly
described in Supplementary Materials and methods section, while
details regarding hiPS lines generation and validation are described
elsewhere (Kyrkou et al., in press).
2.1. Phenotypic characterisation of hiPS-MSCs and hAT-MSCs
Phenotypic characterisation of culturedMSCswas performed at pas-
sage 3 to evaluate the expression of markers speciﬁc for MSC,
haematopoietic, and endothelial lineages (PE-conjugated antibodies
and isotypes in Supplementary Table 4). Flow cytometrywas performed
using CyFlow (Partec, Münster, Germany). Brieﬂy, a total of 2 × 105 cul-
tured cells were stained with PE-conjugated antibodies, and dead cells
were excluded using 2 μg/ml 7-Amino-actinomycin D (7-AAD) viability
staining solution (Invitrogen).
2.2. Multipotency of hiPS-MSCs and hAT-MSCs
Cultured MSCs were expanded in vitro under standard conditions to
passage 3 (p3) and then subjected to differentiation induction
protocols. Osteogenic differentiation was performed using standard
osteoinduction conditions and semi-quantitative assessment of osteo-
blast differentiation was performed using the alkaline phosphatase
(ALP) activity assay. Visual assessment ofmineralisationwas performed
using Alizarin Red S (Sigma) (Jones et al., 2002). Chondrogenic differen-
tiation was performed using standard protocols in pellet cultures and
semi-quantitative assessment of chondrogenesis was performed using
Toluidine blue stain (Sigma) (Jones et al., 2002). Adipogenic differenti-
ation was performed using standard adipoinduction conditions and
evaluated using 0.5% Oil Red (Sigma) as previously described (Jones
et al., 2002). Quantitative real-time PCR (qPCR) to investigate transcript
expression of hAT-MSCs and hiPS-MSCs is described in Supplementary
Materials and methods section.
2.3. Human AT-MSC seeding on biomaterial and differentiation towards
ligament and osteogenic cells
Matrigel was thawed for 24 h at 4 °C. Passage 3 hAT-MSCs were
trypsinised (as described above), centrifuged and embedded in thawed
Matrigel matrix at a ratio of 2 × 106 cells per 100 μl. The hAT-MSCs/
Matrigel mix was placed on the Leeds-Keio biomaterial (static seeding).
Onday 7 post-seeding the constructwas rinsedwith PBS,ﬁxedwith 10%
formaldehyde for 10 min and stained with YOYO-1 (1:10,000,
Invitrogen) for 20 min. The morphology and attachment of the cells
on the biomaterial was visualised by Leica TCS SP5 confocal microscope
(10× dry objective).
Three dimensional differentiation of hAT-MSCs on Leeds-Keio was
performed in a way to closely mimic normal human ACL's structure
compartmentalisation in vivo. Two separate induction strategies were
employed. Ligament-induction was assessed by mixing 1 × 106 cells
with 5 ng/ml TGF-β and 3 ng/ml FGF-2 (both from PeproTech, Rocky
Hill, USA) and embedding them in 50 μl Matrigel (LMC). Osteogenic-
induction was assessed by mixing 1 × 106 cells with 100 ng/ml BMP-2(PeproTech) and 3 ng/ml FGF-2 and embedding them in 50 μl Matrigel
matrix (OMC). The LMC was directly applied to the central part of the
biomaterial whereas OMC was directly applied to the lateral ends of
the biomaterial, and left to solidify on the biomaterial for 20 min at
37 °C in a 100 mm dish. Medium was refreshed every 72 h with ADSC
(Lonza) and the differentiation assay was terminated at day 21. The
whole transcriptome molecular proﬁling of hAT-MSC implants is
described in Supplementary Materials and methods section.
2.4. Human iPS-MSC seeding on biomaterial and differentiation towards
ligament and osteogenic cells
Human iPS were precommitted towardsmesodermal fate by gradu-
ally replacing mTeSR with ADSC expansion medium. Brieﬂy, after man-
ual passaging hiPS' clumps were seeded on standard culture matrigel
coated dishes. The ﬁrst 2 days cells were fed with mTeSR, the following
2 daysmTeSRwas diluted 4:1 with ADSCmedium. Day 5–6 the dilution
was 1:1 and the last 2 days 1:4. Committed cells (hiPS-MSCs) were
trypsinised, neutralised, centrifuged and resuspended in 100 μl of
ADSC medium. Resuspended cells were split into two equal fractions
each one used to form the ligament-induction and osteogenic-
induction strategies, respectively. Three dimensional differentiation of
committed cells on Leeds-Keio was performed as described above. The
whole transcriptome molecular proﬁling of hiPS-MSC implants is de-
scribed in Supplementary Materials and methods section.
2.5. Implant placement in a swine ACL injury model
Six Landrace × LargeWhite swine (3months old, 25–30 kg)were di-
vided into experimental groups: three animals were treated with hiPS-
MSC/biomaterial implant, two animals with hAT-MSC/biomaterial im-
plant, and one animal with biomaterial alone. Both ends of shaft were
sutured with double leader line 80 lb. (Veterinary Instrumentation,
Shefﬁeld, UK). The lateral parapatellar arthrotomy was used to expose
the right knee joint and specially the ACL, without harming the fat pad
or other tissues of the knee joint. After the excision of the ACL, the fem-
oral and tibial bone tunnels were created with a 5.0 mm diameter drill
bit. The shaft was passed through the bone tunnel and joint cavity and
both ends were ﬁxed by crimp clamp at the lateral side of the joint
ﬂexed at 30° with the implant in slight tension. Four months post-
surgery, the animalswere euthanisedwith a bolus dose of pentobarbital
sodium euthanasia solution (Dolethal, Vetoquinol) at a dose of 2 ml/kg
and thewhole kneewas removed for morphological and immunohisto-
chemical evaluation of ACL reconstruction. The anatomical preparation,
sequencing and histological analysis of ACL tissues is described in Sup-
plementary Materials and methods section.
3. Results
3.1. Mesodermal commitment of hiPSCs
Human iPSCswere committed to themesodermal lineage by replac-
ing mTESR with ADSC medium and gradually increasing the FCS con-
centration to 10% (Fig. 1A). This commitment protocol resulted in the
generation of two MSC-like populations, early and late MSC-like cells
(hiPS-MSCs), 10 and 20 days post-induction, respectively. hiPSC cell col-
onies gradually became round CFU-F colonies containing characteristic
MSC-like spindle shaped cells (Fig. 1B). The CFU-F yield was 239, 291,
256 colonies per 104 cells seeded at passage 3 for hiPS-MSC lines 1, 2
and 3, respectively. Single cells representing the stem cell population
were gated (R1), excluding cell doublets and cell debris from our anal-
ysis, and constituted the ﬁrst step of the gating strategy leading to
distinct cell populations (A1, A2) generated by staining with PE-conju-
gated speciﬁc markers against cell surface epitopes (Fig. 1C). Surface
phenotyping of hiPSC-MSCs was carried out using an abundance of sur-
facemarkers used to characterise passage 3 hAT-MSC cultures (see later
Fig. 1.Mesodermal commitment of hiPS: A) Commitment protocol of hiPS towards mesenchymal cell fate. B) Colony-Forming-Unit (CFU) assay of generated hiPS-MSCs. CFU-F colonies
consisting of at least 50 cells were generated 10 days post-hiPS-MSC seeding in vitro C) Gating strategy of two-colour ﬂow cytometry analysis. FSC and SSC parameters were used to gate
the actual hiPS-MSC population by excluding all debris, cell doublets and dead cells. All surfacemarkers usedwere conjugated to PE ﬂuorochrome. D) Phenotypic proﬁling of hiPS cultures
pre- and post-mesodermal commitment. Surface marker phenotyping of hiPS from the pluripotent state, to the early MSC-like state and ﬁnally, the late MSC-like state (hiPS-MSCs).
Commitment process of hiPS results in gradual decrease of pluripotency markers and acquisition of MSC characteristics.
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CD15, CD45, CD235α) and endothelial cell surface markers (CD31) was
very low or absent, whereas keyMSC (CD29, CD44, CD73, CD105, CD90)
and pericytic (CD201, CD140α and CD140β) markers were highly
expressed (Fig. 1D).Chondrogenic induction of hiPSC-MSCs in 3-D pellet cultures result-
ed in good chondropellet formation and production of highly sulfated
glycosaminoglycans in all three clones (Fig. 2A, upper two rows). Oste-
ogenic induction resulted in the differentiation of hiPS-MSCs into oste-
oblasts in 2-D cultures that was associated with high ALP activity in all
Fig. 2.Multipotentiality of committed hiPS: A) All hiPS-MSC lines showed tripotentiality. Shiny, round chondropellets rich in sGAGs are generated 15 days post-chondroinduction in vitro
(upper two panels). Osteogenic induction of hiPS-MSCs results in ALP+ osteocultures with high levels of mineralisation (middle two panels) on day 21. Multiple, tiny (grade 2) lipid
droplets are evident within cell cytoplasm 21 days post-adipoinduction of hiPS-MSC lines. B) qPCR validation of trilineage differentiation (chondrogenesis-, osteogenesis- and
adipogenesis-related transcript expression analysis in upper, middle and bottom panels, respectively). All hiPS-MSC lines show upregulation of individual lineage-related transcripts
when compared to AT-MSC cultures. C) Generated hiPS-MSCs show similar phenotypic proﬁle to hAT-MSCs. Interestingly, hiPS-MSCs had signiﬁcantly higher expression levels of
CD146 (MSC/endothelial marker) and CD324 (pluripotency marker) compared to hAT-MSCs (p b 0.05).
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(Fig. 2A, twomiddle panels). Adipogenic induction resulted in early ad-
ipocyte formation in all hiPS-MSC lines as their lipid accumulationwith-
in the cell cytoplasm was limited (Fig. 2A, bottom panel) with
adipocytes ranked as grade 2 (English et al., 2007) and differentiation
efﬁciency approx. 20% of the whole culture. Mesodermal commitment
of the hiPSC-MSCs to chondrogenic, osteogenic and adipogenic direc-
tions was complemented with evaluation of early and late lineage-
speciﬁc molecules of each mesodermal lineage (Fig. 2B). The progress
of mesodermal commitment of hiPS indicated the gradual loss of
pluripotency (Supplementary Fig. 2). The expression of CD324
pluripotency marker molecule (Li et al., 2010) was gradually decreased
during mesodermal commitment of hiPS as expected, suggesting the
mesoderm-restricted proﬁle of the generated hiPS-MSCs. Differentia-
tion of hiPS to hiPS-MSC lines did not induce chromosomal abnormali-
ties as seen by CGH analysis (Supplementary Fig. 1B).
3.2. Isolation, characterisation and further mesodermal differentiation of
hAT-MSCs
Wehave used the stromal-vascular fraction (SVF) of supra-adventitial
and perivascular areas (Zimmerlin et al., 2013) to generate primary hAT-
MSC cultures that gave rise to adherent ﬁbroblast-like cells(Supplementary Fig. 3 Ai) and in vitro CFU-Fs (Supplementary Fig. 3 Aii)
2 days and 10 days post-seeding, respectively.ΑΤ-derived CFU-F frequen-
cy was higher than that reported in BM aspirates (430–600 CFU-Fs/106
versus 10–100 CFU-Fs/106 mononuclear cells seeded), which is still the
‘gold standard’ for autologous therapy (Castro-Malaspina et al., 1980;
Jones and McGonagle, 2008). The hAT-MSC culture at P3 was capable of
differentiating towards osteoblasts (Supplementary Fig. 3 Bi & ii), and ad-
ipocytes (Supplementary Fig. 3 Biii &iv) in 2-D cultures and towards
chondroblasts in 3-D pellet cultures (Supplementary Fig. 3Bv & vi) irre-
spective of the age of the donor (donor ages 38, 77, 78 years-old). More-
over, the hAT-MSC cultures exhibited a surface marker proﬁle uniformly
compatible with the MSC phenotype, with the exception of the CD146
marker, which showed remarkably low levels of expression (Supplemen-
tary Fig. 3 C), probably deriving fromserial passaging as shownpreviously
for BM-MSCs (Dominici et al., 2006). The hAT-MSC cultures were of high
purity being negative for endothelial cell- (CD31) and haematopoietic
cell-markers (CD14, CD15, CD45, CD235α) (Supplementary Fig. 4,
upper panel) and highly positive (N80%) for major MSC markers (CD29,
CD44, CD73, CD105, CD90) [ISCT criteria (Dominici et al., 2006)] (Supple-
mentary Fig. 4, middle panel). Interestingly, hAT-MSCs highly expressed
some pericytic markers (CD201, CD140α and CD140β) (Supplementary
Fig. 4, bottompanel) directly related to the high vascularity and increased
MSC to endothelial cell interactions in adipose tissue (Ryu et al., 2013).
452 D. Kouroupis et al. / Stem Cell Research 17 (2016) 448–457Moreover, the CD201 expression has been associated with distinct hAT-
MSC subsets in vitro (Baer et al., 2013). Extensive culturing did not result
in chromosomal abnormalities as demonstrated byCGHanalysis (Supple-
mentary Fig. 1 A).Close comparison revealed that hAT-MSCs and hiPSC-MSCs actually
exhibit very similar mesenchymal surface marker proﬁles (Fig. 2C), the
only exception being the considerably higher expression of the
perivascular marker CD146 (Sacchetti et al., 2007) in hiPSC-MSCs,
453D. Kouroupis et al. / Stem Cell Research 17 (2016) 448–457associating themwith vascular smoothmuscle commitment and ascrib-
ing a myoﬁbroblastic character to the hiPSC-MSCs (Espagnolle et al.,
2014). Genome-wide transcriptome comparison of hAT-MSCs and the
hiPSC-MSCs revealed that 70% (915 out of 1412) of the up-regulated
transcripts during the commitment of hiPSs towards hiPS-MSCs are
also found highly expressed in hAT-MSCs compared to pluripotent
hiPSCs, supporting the mesenchymal identity of hiPS-MSCs (Supple-
mentary Fig. 5). Indeed, angiogenesis, ossiﬁcation, connective tissue
functions and epithelial to mesenchymal transition (EMT) were
among the biological processes that were increased in graphs illustrat-
ing the top 200 (p b 0.005) biological processes that are enriched in
hiPSC-MSCs and hAT-MSCs, when compared to pluripotent hiPSCs
(Supplementary Fig. 5 B).3.3. Generation and validation of the 3-D bioartiﬁcial anterior cruciate
ligament (baACL)
Though there is a vast choice of biomaterials, we have used the
Leeds-Keio biomaterial due to its previous use in orthopaedic
operations (Chen et al., 2009). Moreover, both the hAT-MSCs and
the hiPS-MSCs showed excellent homing capacity on its ﬁbres
4 days post-seeding, as shown by YOYO-1 staining (Fig. 3A). To gen-
erate an implantable bioartiﬁcial ACL, we have seeded either hAT-
MSCs or hiPSC-MSCs along the entire length (10 cm) of the 3-D bio-
material in Matrigel. In the central 4 cm part, the Matrigel contained
TGF-β/FGF-2 for differentiation towards the ﬁbrous ligament,
whereas on the last 3 cm of each end of the biomaterial, the Matrigel
was supplemented with BMP-2/FGF-2 to develop the osseous bone
attachment (Fig. 3B), corresponding to the average dimensions of
each part of the normal ACL in humans (Kopf et al., 2011). Confocal
and scanning electron microscopy revealed that hAT-MSCs and
hiPSC-MSCs, at day 21 post-seeding, had proliferated well on both
the ﬁbrous and osseous part the Leeds-Keio biomaterial forming
multiple cell layers that started to anastomose into the open pores
of the scaffold (Fig. 3C). The high expansion capacity of cells on the
biomaterial was also conﬁrmed on the surface of (1 mm and
200 μm images in both left and right panels) and within the individ-
ual ﬁbres of the biomaterial (50 μm) (Fig. 3D).
Genome-wide transcriptome analysis of the hAT-MSCs or the
hiPSC-MSCs that were induced to differentiate either to the osseous
or the ligamentous part of the ACL showed considerable similarity in
gene regulation circuits during differentiation. Indeed, differentia-
tion of hAT-MSCs, by TGF-β/FGF-2, towards ligament in the ﬁbrous
part of baACL leads to the up- and down-regulation of 183 and 51
genes, respectively (Fig. 3E), whereas differentiation in the osseous
part using BMP-2/FGF-2 leads to 191 and 56 genes up- and down-
regulated respectively (Fig. 3E). Interestingly, from the up- and
down-regulated genes, 179 and 50, respectively, were commonly
detected both in the osseous and the ﬁbrous part of the baACL con-
struct. Thus, concerning differentiation of hAT-MSCs to bone there
were only 12 and 6 genes that were speciﬁcally up- and down-
regulated, respectively (Supplementary Table 1), the numbers
being even smaller in differentiation of hAT-MSCs to the ﬁbrous
part in which only 4 and 1 genes were up- and down-regulated, re-
spectively (Supplementary Table 1). Similarly, a considerable num-
ber of genes were commonly regulated in the ﬁbrous and osseousFig. 3. hAT-MSCs and hiPS-MSCs simultaneous 3D differentiation towards osseous and ﬁbrous t
biomaterial ﬁbres 4 days post-seeding, as shown by YOYO staining of cells' DNA. B) Graphical
experiments. hAT-MSCs or hiPS-MSCs are initially mixed with Matrigel matrix and different
FGF-2 growth factors in the central and the ends of the biomaterial, respectively. C–D) Confoc
the osseous and ﬁbrous parts of the scaffold. Both hAT-MSCs and hiPS-MSCs show good prolif
the scaffold. E) Graphical illustration of microarray analysis of hAT-MSCs and hiPS-MSCs post
transcripts and 50 downregulated transcripts were common between the ﬁbrous and osseou
transcripts were common between ﬁbrous and osseous parts of the implant.parts of the baACL construct during differentiation of hiPSC-MSCs
(Fig. 4E) resulting in a small set of differentially regulated genes
(Supplementary Table 2).
3.4. Therapeutic validation of the bioartiﬁcial ACL (baACL) in a swine ACL
injury model
The baACL generated using hAT-MSCs or hiPSC-MSCs was validated
concerning its therapeutic properties using a swine ACL injury model.
Towards this purpose, the baACL was transplanted between the attach-
ments of the anteromedial (green in Supplementary Fig. 6) and the pos-
terolateral (purple in Supplementary Fig. 6) bundles of the ACL in order
to support the movement of the femoral and tibial bones. After
4 months, PET-CT scanning demonstrated that in all experimental ani-
mals, irrespective of whether the baACL was prepared with hAT-MSCs
or hiPSC-MSCs, the area of the graft was metabolically active, whereas
in the control animal the implantation area was devoid of metabolic
turnover (Fig. 4A). Sequencing of PCR-ampliﬁed DNA from the baACLs
with primers recognising the human TAS1R3 gene, (Fig. 4B) indicated
that 4 months after implantation a considerable part of the tissue de-
rives from either the hAT-MSCs or the hiPSC-MSCs.Macroscopically, re-
generated ACL had a thickness of 1.5 cm, whereas in control animal
(acellular biopolymer only) there was almost no tissue formation and
severe osteoarthritic lesions (markedwith arrows) in both femoral con-
dyles (Fig. 4C).
Structural evaluation of the reconstructed hAT-MSC or hiPS-MSC
ACL showed a triphasic tissue formation (Fig. 4D). Osseous areas
consisted of numerous biomaterial ﬁbres embedded within newly
formed bone (marked as weak red) and surrounded by mature bone
(marked as intense red) (Fig. 4D i). Fibrous areas contained numerous
aligned ﬁbres with embedded ﬁbroblasts (Fig. 4D iii) that were
surrounded by groups of vessels indicating the blood supply to the
newly formed tissue (Fig. 4D iv). Finally, a transition zone was evident
in between the ﬁbrous and osseous parts consisting of mature cartilage
with embedded chondroblasts (marked with asterisks, Fig. 4D ii). Im-
munohistochemical evaluation of reconstructed ACL revealed Vimentin
and αSMA expression characterising the embedded ﬁbroblasts and the
numerous vesselswithin the ﬁbres, respectively (Fig. 4E). Also, Collagen
I and III were present in the ﬁbrous parts of both reconstructed hAT-
MSC and hiPS-MSC ACLs being more highly expressed in the latter
(Fig. 4E). Importantly, in the implanted baACLs prepared with either
hAT-MSCs or hiPSC-MSCs, there was no indication of graft versus host
disease (GVHD). Indeed, throughout the entire length of the recon-
structed ACL in both ﬁbrous and osseous parts, there were no signs of
CLA (cutaneous lymphocyte-associated antigen, expressed by T cells of
the cutaneous system), CD68 (expressed by monocytes/macrophages)
and CD138 (Syndecan-1, expressed by plasma cells) expression (Sup-
plementary Fig. 7). The immunoregulatory and anti-inﬂammatory
properties of MSCs are well documented (Bartholomew et al., 2002;
Ghannam et al., 2010).
3.5. Chondrogenic potential of hAT-MSC and hiPS-MSC implants as a
validation to reconstruct the transition zone in vivo
Human AT-MSC and hiPS-MSC baACL implant transplantation in a
swine ACL injury model resulted in a triphasic tissue formationissue: A) Both hAT-MSCs or hiPS-MSCs show excellent homing capacity on the Leeds-Keio
illustration of the 3-D simultaneous differentiation model on the biomaterial used in our
iation towards ﬁbrous and osseous fates is induced by adding TGF-β/FGF-2 and BMP-2/
al microscopy and scanning electron microscopy imaging of hAT-MSCs or hiPS-MSCs on
erative capacity by forming multiple cell layers which anastomose into the open-pores of
-osteogenic and ﬁbroblastic induction on the biomaterial. In hAT-MSCs, 179 upregulated
s parts of the implant. In hiPS-MSC implants, 175 upregulated and 279 downregulated
454 D. Kouroupis et al. / Stem Cell Research 17 (2016) 448–457consisting of ﬁbrous, osseous, and transition zones. Previous studies
have shown that physiologically human ACL contains a gradual transi-
tion from bone, mineralised ﬁbrocartilage and ﬁbrocartilage, into the
ligament substance (Lui et al., 2010). We hypothesised that in our re-
constructed ACLs the transition zone originates from the intermediate
area between the ﬁbrous and osseous zones of 3-D implant generation
model as a result of growth factor inﬂux from both zones. To test this
hypothesis in 2-D cultures, hAT-MSCs and hiPS-MSCs were initially in-
duced by all three growth factors involved (TGF-β, BMP-2, FGF-2) in im-
plant generation for 21 days and then differentiated in specialised
medium towards chondrogenesis for 15 days (Fig. 5). Both GF induced
hAT-MSC and hiPS-MSC cultures show high sGAG content in 2-D and
3-Dmicromass chondrogenic conditions at day 15 (Fig. 5A, left andmid-
dle panels) and high expression of chondrogenesis-related markers
(SOX9, HAPLN1, COMP, ACAN, COL1A2, COL3A1, COL10A1) (Fig. 5B;
undifferentiated hAT-MSCs and hiPS-MSCs show low expression of
chondrogenesis-related markers, data not show). Also, their high com-
mitment to chondrogenic fate was evident by very rare ALP+ osteo-
blasts identiﬁed in the culture (right panels). The chondrogenic
capacity of the implants generated by 3-D simultaneous differentiation
modelwas also tested. The different zones generatedwere split and cul-
tured for 15 days in specialised chondrogenic medium (Fig. 5C). Both
hAT-MSC and hiPS-MSC implants showed signiﬁcantly (p b 0.05) higher
expression of chondrogenesis-related transcripts in osseous or transi-
tion zones compared to the ﬁbrous zone. These results reinforce the
concept that transition tissue in vivo originates from either osseous or
transition zones of hAT-MSC and hiPS-MSC implants generated ex vivo.
4. Discussion
We have generated bioartiﬁcial ACL grafts by differentiating hAT-
MSCs or hiPS-MSCs on Leeds-Keio biomaterial to form a ligamentous
part in the center and two osseous sections at both ends. We reckoned
that ossiﬁcation on both ends of a baACLwould provide stronger attach-
ment on the femur and tibia imitating the origin and insertion of the
ACL. Indeed, evaluation using a swine ACL injury model revealed that
the generated baACL constitutes a successful proof-of-principle ap-
proach for the treatment of ACL rupture that can be used either in repair
or reconstruction ACL therapies.
Human AT-MSCs are well-characterised in many studies constitut-
ing a solid reference point to compare the efﬁciency of hiPSC-based
cell therapies. The isolated hAT-MSCs complied with the criteria set by
the Mesenchymal and Tissue Stem Cell Committee of the International
Society for Cellular Therapy (ISCT) (Dominici et al., 2006). We generat-
ed hiPSCs from human foreskin ﬁbroblasts (HEFs) using a modiﬁcation
of the footprint-free episomal strategy (Okita et al., 2011). All
established hiPS clones were positive for characteristic embryonic
markers, their microarray proﬁle was identical to embryonic stem
cells (HUES1) and they could generate all three germ layers in vivo
(Kyrkou et al., in press). Previous published studies have demonstrated
the derivation of MSCs from hiPSs through the inhibition of TGF-β path-
way (Chen et al., 2012), the supplementation with various growth fac-
tors (Niwa et al., 2011) or the induction with MSC-conditioned
medium (Lee et al., 2014). In the present study, hiPS-MSCswere derived
through alteration of the serum free hiPS medium to a serum-based
specialised MSC medium. This simple method resulted in mesengenic
progeny possessing the characteristic features of MSCs 20 days post-
commitment in vitro. These hiPS-MSCs exhibited self-renewal capacity,
tripotentiality and MSC-related phenotypic proﬁle.
Direct comparison of hAT-MSC and hiPS-MSC phenotypic proﬁles
exhibited high similarity in expression levels for all mesenchymal,
pericytic, haematopoietic and endothelial markers tested. Interestingly,
CD324 (E-Cadherin) is highly expressed (~72%) in hiPSC colonies and
strongly downregulated (~12%) in hiPSC-MSC post-mesodermal com-
mitment indicating that loss of E-Cadherin-mediated cell–cell contacts
occurs during epithelial to mesenchymal transition leading to theacquisition of a mesenchymal phenotype, as expected (Cavallaro and
Christofori, 2004; Bates and Mercurio, 2005). In parallel, CD146
(MCAM) expression is strongly increased (from ~46% to 92%) in
hiPSC-MSC post-mesodermal commitment suggesting that CD146 is
either an inducer of epithelial to mesenchymal transition (Zeng et al.,
2012) or simply correlates with an MSC subpopulation located in
perivascular tissue niches possessing a vascular smooth muscle pheno-
type (Espagnolle et al., 2014).
Genome-wide transciptome microarray analysis of hAT-MSCs and
hiPS-MSCs revealed high similarity of upregulated transcripts between
these mesenchymal populations versus the basal pluripotent stem cell
state (hiPS). Importantly, a recent study using human platelet serum
to establish hiPS-MSCs, revealed a close relationship between MSCs
and generated hiPS-MSCs in their global gene expression proﬁle
(Frobel et al., 2014). In the present study, the common top 200
(p b 0.005) enriched Biological Processes of hAT-MSCs and hiPS-MSCs
when compared to the pluripotent background of hiPS indicated an in-
creased tendency of these progenitors to be involved in functional pro-
cesses related to angiogenesis, ossiﬁcation, connective tissue formation
and epithelial to mesenchymal transition. Similarly, in a previous study
hiPSCs commitment to hiPS-MSCs resulted in the upregulation of
mesodermal genes (MSX2, NCAM, HOXA2) and downregulation of
pluripotency genes (OCT4, LEFTY1/2) in early cultures (10 days). In the
same study, low-throughput microarray analysis of hiPS-MSC late cul-
tures (passage 3) indicated increased expression of genes related to ep-
ithelial to mesenchymal transition (Chen et al., 2012). Taken together,
these results point to the fact that hiPSC-MSC is amesenchymal popula-
tion closely related to hAT-MSCs.
To the best of our knowledge, the simultaneous in vitro reconstruc-
tion of both ﬁbrous and osseous zones in order to produce a viable
baACL construct has not been used before. For this purpose, two growth
factor cocktails have been applied, a ligament inducing (TGF-β/FGF-2)
in the middle part and a bone forming (BMP-2/FGF-2) in both ends of
the biomaterial. Genome-wide transciptome analysis of the ligamen-
tous and osseous zones from hAT-MSC and hiPS-MSC baACLs allowed
us to make the following statements. The differentiation of hAT-MSCs
to the ligamentous and osseous parts of the biopolymer proceeds with
a gene expression pattern that is surprisingly similar. Indeed, when
compared to the undifferentiated hAT-MSCs, the up-regulated tran-
scripts in the ﬁbrous (183) and the osseous (191) parts were mostly
common (179), even though the inducer was different TGF-β/FGF-2 vs
BMP-2/FGF-2. The same applied for the down-regulated transcripts
too (from the 51 and 56 down-regulated transcripts in the ﬁbrous and
osseous parts, respectively, 50 were common). The same was observed
in the case of hiPSC-MSCs' transcriptome at the end of ﬁbrous and osse-
ous differentiation on the scaffold versus the transcriptome of pre-
seeded hiPSC-MSCs, except that the number of the down-regulated
transcripts was much higher. Indeed, from the up-/down-regulated
transcripts in the ﬁbrous (205/337) and the osseous parts (196/285)
the great majority were common (175/279). Considering that both
cocktails contain FGF-2 and that BMP-2 activates SMAD1/5/8, an activa-
tion that can be also accomplished by TGF-β via ALK1, then perhaps
such a similarity in the expression pattern is not so surprising. How-
ever, the presence of small quantities of BMP-2 are capable of driving
the differentiation to bone under these circumstances. In addition,
small up-regulation of common ligament- and osteo-related tran-
scripts may be attributed to the speciﬁc concentrations used in
TGF-β/FGF-2 and BMP-2/FGF-2 cocktails, respectively. In further
studies, different growth factor concentrations could yield more
striking transcriptome differences between ﬁbrous and osseous
parts.
Indeed, both hAT-MSC and hiPS-MSC baACL implants, when validat-
ed in a swine ACL excision model, resulted in proper ACL tissue forma-
tion. In the osseous zones, both in the tibia and the femur, the ﬁbres of
the biomaterial were surrounded by newly formed tissue that was en-
capsulated within mature bone. Fibrous zones consisted of wavy
Fig. 4.Anterior cruciate ligament reconstructionwith hAT-MSC- or hiPS-MSC-implants 4months post-implantation in a swine ACL injurymodel: A) PET-CT scanning showed regeneration
only in hAT-MSC and hiPS-MSC implant treated animals (white bands within the area of swine knee joint). B) Nucleotide sequence alignment of TAS1R3 between human and swine
species indicates the presence of both species genetic material (dual nucleotide peaks marked with arrows) in reconstructed hAT-MSC and hiPS-MSC ACL tissues. C) Both hAT-MSC
and hiPS-MSC implants resulted in in vivo reconstruction of ACL tissue. Representative micrographs of normal swine ACL, reconstructed ACL, and control knee. D) Both hAT-MSC and
hiPS-MSC implants resulted in the formation of three distinct zones in vivo: osseous, ﬁbrous, and transition zones. (i) Osseous zone shows individual bone-forming nodules within
both tibia and femur bones consisting of numerous biomaterial ﬁbres surrounded by newly formed osteoblasts (marked with black asterisks) and mature bone (white asterisks). (ii)
Transition zone consisting of both cartilaginous area (marked with black asterisk) and Sharpey's ﬁbres area. (iii) Fibrous zone consisting of numerous parallel aligned collagen ﬁbres
where individual ﬁbroblasts are embedded. (iv) Multiple vessels are neighbouring the collagen ﬁbres (black arrows). E) Immunophenotyping of hAT-MSC and hiPS-MSC reconstructed
ACL tissues reveal positive expression of Vimentin, αSMA, Collagen I and III markers in the ﬁbrous zone of the implants. The negative control is desmin.
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Vimentin-positive ﬁbroblasts. Importantly, capillary islets
surrounded the collagen ﬁbres, especially in close proximity to the
femoral and tibial attachments, indicating a developed blood supply
to the newly formed tissue. Thus, both hAT-MSC and hiPS-MSC im-
plants resulted in ACL tissue formation structurally and qualitatively
reminiscent of the normal ACL, in comparison to the sole biomaterial
implantation which did not result in any signiﬁcant tissue regenera-
tion. Moreover, 4 months post-baACL graft implantation TAS1R3
gene DNA sequencing of the reconstructed ACL tissue indicated the
ample presence of sequences of human origin, whereas the swinegenetic material was less but still clearly detectable. Experimental
swines uniformly exhibited neither signs of discomfort of the operat-
ed knee nor ﬁndings of osteoarthritis after sacriﬁce, in clear distinc-
tion to the controls.
Though the results using baACL grafts equipped with hAT-MSCs or
hiPSC-MSCswere similar, this does not necessarily indicate the utilisation
of commonmolecularmechanisms. In fact, we have observed striking dif-
ferences between hAT-MSCs and hiPSC-MSC in the number of genes that
were down-regulated during differentiation to the ligamentous (51 vs
337) and osseous parts (56 vs 285). Also in the up-regulated genes the
number of commonly regulated genes was small (16 out of 183/205 in
Fig. 5. Generation of cartilaginous transition zone ex vivo: A) Chondrogenic differentiation for 15 days of GF-induced (FGF-2/TFGβ/BMP-2) hAT-MSCs and hiPS-MSCs resulted in high
sGAGs production in both 2-D (left panel) and micromass (middle panel) cultures. Differentiated cultures show very few alkaline phosphatase (ALP) positive cells (right panel).
B) Both GF-induced hAT-MSCs and hiPS-MSCs cultured show upregulated expression of chondrogenic markers (SOX9, HAPLN1, COMP, ACAN, COL1A2, COL3A1, COL10A1) by qPCR.
Normalisation of selected transcripts expression levels relative to control GAPDH housekeeping transcript is performed using the formula: 2−ΔCt, ΔCt = Expression value (selected
transcript) − expression value (housekeeping transcript). C) Micrograph schematic of three distinct zones generated post-GF induction on the biomaterial ex vivo. Subsequent
chondrogenic differentiation of separate zones was evaluated using a panel of chondrogenesis-related markers by qPCR. Most markers were signiﬁcantly (*p b 0.05, **p b 0.01,
***p b 0.001) upregulated in osseous and transition zones.
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fore, it is not impossible to conceive that alternative transcriptional ma-
chineries are utilised between hAT-MSCs and hiPSC-MSCs during
differentiation to the ligamentous or the osseous parts of the baACL con-
struct. Indeed, hiPSC-MSCs do express high levels of CD146+, whereas
hAT-MSCs are CD146−. CD146 is an endothelial and subendothelial
marker (Bardin et al., 1998). Concerning the role of CD146, high expres-
sion of CD146 was associated with commitment to a vascular smooth
muscle cell (VSMC) lineage, whereas there was no substantial difference
in osteogenic, adipogenic and chondrogenic differentiation or in vitro
haematopoietic supportive activity between CD146−/Low and CD146High
MSCs (Espagnolle et al., 2014). However, in a knockdown approach in
human MSCs, it was found that CD146 was involved in proliferation
and osteogenic differentiation (Stopp et al., 2013). As VSMCs osteogenic
differentiate under the inﬂuence of the appropriate inducer (Johnson
et al., 2006), then differentiation of a CD146+ MSC to osteoblast via an
VSMC intermediate would probably require a different transcriptional
programme comparing to a direct differentiation of an CD146−MSC pro-
genitor to osteoblast. Likewise in pathological heterotopic ossiﬁcationdiseases, bone formation outside the skeleton occurs with entirely differ-
ent mechanisms. This is clearly exempliﬁed by two rare disinherited dis-
orders, the ﬁbrodyslasia ossiﬁcans progressiva (FOP) and the progressive
osseous heteroplasia (POH). ACVR1 gene mutations are responsible for
FOP inducing heterotopic endochondral ossiﬁcation. POH leads to the
generation of predominantly intramembranous bone tissues due to
GNAS gene mutations (Shore and Kaplan, 2010).
Tissue-engineered grafts are commonly classiﬁed as class III med-
ical devices that require FDA approval for clinical applications.
Therefore, many hurdles exist in developing and testing bioartiﬁcial
grafts for ligament injuries in humans. In our study we successfully
tested the baACL grafts in a swine joint that resembles the structure
and mechanical forces of the normal human joint. Importantly, both
baACL grafts equipped with hAT-MSCs or hiPSC-MSCs showed
triphasic tissue structure (ﬁbrous, osseous, transition zones) where-
as experimental swines showed no signs of discomfort and osteoar-
thritis. In further studies, baACL graft generation using animal-free
culture conditions and bioabsorbable scaffolds will fullﬁl FDA re-
quirements. Overall, the present study implies that both hAT-MSC
457D. Kouroupis et al. / Stem Cell Research 17 (2016) 448–457and hiPS-MSC baACL implants have great potential in future clinical
applications.
5. Conclusion
These results provide proof-of-principle data suggesting that stem
cells combined with tissue engineering are able to provide solutions
that can be applied either to ACL repair or reconstruction therapies. In
reconstruction approaches, in which the entire ACL is replaced by a
bioartiﬁcial ACL the development of approaches to match the anatomi-
cal structure of every knee is critical to reduce the postoperative OA. In
simple repair, best results concerning the appearance of OA and other
long-term consequences will be achievable through the regeneration
of the damaged tissue only using stem cells and advanced scaffolds-
bridges (scaffolds ﬁlling the gaps between the ends of the torn liga-
ments) (Kiapour and Murray, 2014) without any interference with the
local anatomy.
In conclusion,we believe that the present communication clearly in-
dicates that hAT-MSCs andhiPSC-MSCs are both good candidates for the
generation of bioarticiﬁal ACL constructs as tested in a swine ACL rup-
ture animal model. Thus, this study supports the idea and provides
proof-of-principle evidence that ACL ruptures can be treated using
more dynamic and versatile treatment approaches such as those offered
by tissue engineering in which the differentiation ability of stem cells is
combined with the advanced scaffold technology.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2016.04.016.
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